Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
Sponsor: LG Chem
Summary
This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.
Official title: A Phase II, Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Immunogenicity and Safety of DTaP-HepB-IPV-Hib Hexavalent Vaccine LR20062 Versus Hexaxim Administered Intramuscularly in Healthy Infants As Primary Series At 2, 4, 6 Months of Age
Key Details
Gender
All
Age Range
50 Days - 70 Days
Study Type
INTERVENTIONAL
Enrollment
336
Start Date
2024-10-02
Completion Date
2026-04-30
Last Updated
2024-10-01
Healthy Volunteers
Yes
Interventions
LR20062
DTaP-HepB-IPV-Hib vaccine
DTaP-HepB-IPV-Hib vaccine
Control hexavalent vaccine